BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 18832478)

  • 1. Apixaban metabolism and pharmacokinetics after oral administration to humans.
    Raghavan N; Frost CE; Yu Z; He K; Zhang H; Humphreys WG; Pinto D; Chen S; Bonacorsi S; Wong PC; Zhang D
    Drug Metab Dispos; 2009 Jan; 37(1):74-81. PubMed ID: 18832478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans.
    Zhang D; He K; Raghavan N; Wang L; Mitroka J; Maxwell BD; Knabb RM; Frost C; Schuster A; Hao F; Gu Z; Humphreys WG; Grossman SJ
    Drug Metab Dispos; 2009 Aug; 37(8):1738-48. PubMed ID: 19420130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sulfation of o-demethyl apixaban: enzyme identification and species comparison.
    Wang L; Raghavan N; He K; Luettgen JM; Humphreys WG; Knabb RM; Pinto DJ; Zhang D
    Drug Metab Dispos; 2009 Apr; 37(4):802-8. PubMed ID: 19131519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue distribution and elimination of [14C]apixaban in rats.
    Wang L; He K; Maxwell B; Grossman SJ; Tremaine LM; Humphreys WG; Zhang D
    Drug Metab Dispos; 2011 Feb; 39(2):256-64. PubMed ID: 21071521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucuronidation as a major metabolic clearance pathway of 14c-labeled muraglitazar in humans: metabolic profiles in subjects with or without bile collection.
    Wang L; Zhang D; Swaminathan A; Xue Y; Cheng PT; Wu S; Mosqueda-Garcia R; Aurang C; Everett DW; Humphreys WG
    Drug Metab Dispos; 2006 Mar; 34(3):427-39. PubMed ID: 16381667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans.
    Weinz C; Schwarz T; Kubitza D; Mueck W; Lang D
    Drug Metab Dispos; 2009 May; 37(5):1056-64. PubMed ID: 19196845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolism and disposition of 14C-labeled peliglitazar in humans.
    Wang L; Munsick C; Chen S; Bonacorsi S; Cheng PT; Humphreys WG; Zhang D
    Drug Metab Dispos; 2011 Feb; 39(2):228-38. PubMed ID: 20978103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolism and excretion of [(14)C]celecoxib in healthy male volunteers.
    Paulson SK; Hribar JD; Liu NW; Hajdu E; Bible RH; Piergies A; Karim A
    Drug Metab Dispos; 2000 Mar; 28(3):308-14. PubMed ID: 10681375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of age and sex on the single-dose pharmacokinetics and pharmacodynamics of apixaban.
    Frost CE; Song Y; Shenker A; Wang J; Barrett YC; Schuster A; Harris SI; LaCreta F
    Clin Pharmacokinet; 2015 Jun; 54(6):651-62. PubMed ID: 25573421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects.
    Barrett YC; Wang J; Song Y; Pursley J; Wastall P; Wright R; Lacreta F; Frost C
    Thromb Haemost; 2012 May; 107(5):916-24. PubMed ID: 22398784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absorption, metabolism, and excretion of [14C]imidafenacin, a new compound for treatment of overactive bladder, after oral administration to healthy male subjects.
    Ohmori S; Miura M; Toriumi C; Satoh Y; Ooie T
    Drug Metab Dispos; 2007 Sep; 35(9):1624-33. PubMed ID: 17567733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolism, pharmacokinetics, and excretion of the substance P receptor antagonist CP-122,721 in humans: structural characterization of the novel major circulating metabolite 5-trifluoromethoxy salicylic acid by high-performance liquid chromatography-tandem mass spectrometry and NMR spectroscopy.
    Colizza K; Awad M; Kamel A
    Drug Metab Dispos; 2007 Jun; 35(6):884-97. PubMed ID: 17360832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects.
    Kim SD; Kang W; Lee HW; Park DJ; Ahn JH; Kim MJ; Kim EY; Kim SW; Nam HS; Na HJ; Yoon YR
    Clin Ther; 2009 Apr; 31(4):793-803. PubMed ID: 19446152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disposition and metabolism of radiolabeled casopitant in humans.
    Pellegatti M; Bordini E; Fizzotti P; Roberts A; Johnson BM
    Drug Metab Dispos; 2009 Aug; 37(8):1635-45. PubMed ID: 19420128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers.
    Waldmeier F; Glaenzel U; Wirz B; Oberer L; Schmid D; Seiberling M; Valencia J; Riviere GJ; End P; Vaidyanathan S
    Drug Metab Dispos; 2007 Aug; 35(8):1418-28. PubMed ID: 17510248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigating the enteroenteric recirculation of apixaban, a factor Xa inhibitor: administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats.
    Zhang D; Frost CE; He K; Rodrigues AD; Wang X; Wang L; Goosen TC; Humphreys WG
    Drug Metab Dispos; 2013 Apr; 41(4):906-15. PubMed ID: 23386703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of apixaban in healthy Japanese male subjects.
    Yamahira N; Frost C; Fukase H; Yu Z; Wang J; Pursley J; LaCreta F; Hiraoka M
    Int J Clin Pharmacol Ther; 2014 Jul; 52(7):564-73. PubMed ID: 24725442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor.
    Frost CE; Byon W; Song Y; Wang J; Schuster AE; Boyd RA; Zhang D; Yu Z; Dias C; Shenker A; LaCreta F
    Br J Clin Pharmacol; 2015 May; 79(5):838-46. PubMed ID: 25377242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biotransformation of carbon-14-labeled muraglitazar in male mice: interspecies difference in metabolic pathways leading to unique metabolites.
    Li W; Zhang D; Wang L; Zhang H; Cheng PT; Zhang D; Everett DW; Humphreys WG
    Drug Metab Dispos; 2006 May; 34(5):807-20. PubMed ID: 16467134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disposition and metabolism of semagacestat, a {gamma}-secretase inhibitor, in humans.
    Yi P; Hadden C; Kulanthaivel P; Calvert N; Annes W; Brown T; Barbuch RJ; Chaudhary A; Ayan-Oshodi MA; Ring BJ
    Drug Metab Dispos; 2010 Apr; 38(4):554-65. PubMed ID: 20075192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.